PDGFRB and central nervous system cancer: Both sunitinib doses have been shown to result in sufficient plasma concentrations in athymic mice to inhibit VEGFR and PDGFR phosphorylation in xenografts of human melanoma, human glioma, and human colon carcinoma [38].